Blueprint Medicines Corporation (0HOJ.L) LSE

129.40

+0.055(+0.04%)

Updated at July 17 07:31PM

Currency In USD

Blueprint Medicines Corporation

Address

45 Sidney Street

Cambridge, MA 02139

United States of America

Phone

617 374 7580

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

682

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Ms. Kathryn Haviland M.B.A.President, Chief Executive Officer & Director1.69M1976
Mr. Alexis A. Borisy A.M.Co-Founder & Director50,0001972
Ms. Tracey L. McCain Esq.Executive Vice President, Chief Legal & Compliance Officer and Secretary764,9011967
Mr. Michael Landsittel CPAChief Financial Officer974,5681972
Dr. Percy H. Carter M.B.A., Ph.D.Chief Scientific Officer1.1M1971
Ms. Christina Rossi M.B.A.Chief Operating Officer1.22M1976
Dr. Fouad Namouni M.D.President of Research & Development1.23M1969
Ms. Ariel HurleySenior Vice President of Finance and Principal Accounting Officer01974
Ms. Jenna CohenSenior Director & Head of Investor Relations0N/A
Ms. Debra Durso-BumpusChief People Officer01970

Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.